GLP-1 receptor agonists mimic or enhance the action of glucagon-like peptide-1, an incretin hormone involved in post-meal glucose control, insulin secretion, glucagon suppression, gastric emptying, appetite, and satiety
For patients with pre-existing diabetic retinopathy, ophthalmologic follow-up is recommended, particularly during periods of rapid glycemic improvement
Standard GLP-1 treatment follows higher-dose protocols
In SURPASS-AP trial insulin-naive diabetic patients not adequately controlled on therapy with metformin (with or without a sulphonylurea) in Australia, India, China and South Korea, were randomized to TZP 5 mg, 10 mg or 15 mg or insulin glargine
Microdosing GLP-1s may provide support during this transition by helping regulate appetite, energy, and metabolic stability